-
Mashup Score: 9ClinicalTrials.gov - 6 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 26Interleukin 11 therapy causes acute left ventricular dysfunction - 1 month(s) ago
AbstractAims. Interleukin 11 (IL11) was initially thought important for platelet production, which led to recombinant IL11 being developed as a drug to tre
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet-
🙌 IL11 is directly toxic in cardiac myocytes causing calcium handling disturbance and impaired contraction Negatively inotropic in vivo Not just a fibroblast factor Heart failure target? 🤨 https://t.co/uLdqF2N4mL
-
-
Mashup Score: 13The Pathobiology of Interleukin 11 in Mammalian Disease is Likely Explained by its Essential Evolutionary Role for Fin Regeneration - PubMed - 1 month(s) ago
Recent studies have shown IL11 to be pro-fibrotic, pro-inflammatory and anti-regenerative in heart, liver, lung and kidney disease in mice and humans. However, data also show that IL11 is specifically required for appendage regeneration following trauma in some species. In fish, tadpoles and axolotl …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
Nice As predicted: https://t.co/NenxB8HYqY https://t.co/GzMUpMcuPE
-
-
Mashup Score: 23Interleukin 11 therapy causes acute left ventricular dysfunction - 2 month(s) ago
AbstractAims. Interleukin 11 (IL11) was initially thought important for platelet production, which led to recombinant IL11 being developed as a drug to tre
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet-
🙌 IL11 is directly toxic in cardiac myocytes causing calcium handling disturbance and impaired contraction Negatively inotropic in vivo Not just a fibroblast factor Heart failure target? 🤨 https://t.co/uLdqF2N4mL
-
-
Mashup Score: 6
IL6 is a proinflammatory cytokine that binds to membrane-bound IL6 receptor (IL6R) or soluble IL6R to signal via gp130 in cis or trans, respectively. We tested the hypothesis that sgp130Fc, which is believed to be a selective IL6 trans-signalling inhibitor, is in fact a non-spec …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
Timely reminder that the IL-6 (IL-11) trans-signalling idea/field is likely based on an experimental artefact https://t.co/HXnxebNLQk
-
-
Mashup Score: 21Interleukin-11 causes alveolar type 2 cell dysfunction and prevents alveolar regeneration - 3 month(s) ago
Nature Communications – In interstitial lung disease, aberrant KRT8+ basaloid cells impair alveolar repair mechanisms. Here they show that Interleukin-11 expression in KRT8+ cells potentiates their…
Source: www.nature.comCategories: General Medicine News, CardiologistsTweet-
Pssst - its not just IL11 effects on fibroblasts: “These data show that IL11 inhibits reparative AT2-to-AT1 differentiation in the damaged lung to limit endogenous alveolar regeneration, resulting in fibrotic lung disease” Damaging EMT, as seen in kidney https://t.co/osJLsAFHAA
-
-
Mashup Score: 4A combination of the geroprotectors trametinib and rapamycin is more effective than either drug alone - 5 month(s) ago
Genetic suppression of activity of the insulin/IGF/mTORC1/Ras network can ameliorate the effects of ageing in animals. The network provides multiple drug targets because of its role in metabolic disease and cancer, and these are candidates for repurposing for geroprotection. For instance, inhibition of the activity of the mTORC1 complex by rapamycin can extend lifespan in multiple organisms including mice, with early indications of efficacy in humans. Trametinib inhibits MEKs in the Ras pathway and can extend lifespan in Drosophila. However, it is not yet known if trametinib alone or in combination with rapamycin can extend mouse lifespan or improve health at older ages. We assessed survival and health indices of female and male mice treated with trametinib or rapamycin alone, or with the two in combination at the same doses. Trametinib treatment extended lifespan in both sexes, while its combination with rapamycin caused further, additive prolongation. Combination treatment reduced li
Source: www.biorxiv.orgCategories: General Medicine News, CardiologistsTweet-
Trametinib common side effects (BNF): Abdominal pain; anaemia; constipation; cough; dehydration; diarrhoea; dry mouth; fever; haemorrhage; hypersensitivity; infection; intracranial haemorrhage; lymphoedema; nausea; dyspnea; stomatitis; vomiting, etc https://t.co/lORZ1himfQ
-
-
Mashup Score: 27VVB Bio - 5 month(s) ago
VVB Bio is a cutting-edge biotechnology company dedicated to transforming lives through innovative antibody therapeutics.
Source: vvb.bioCategories: General Medicine News, CardiologistsTweet-
It is suggested we do more [5 year] mice studies but how about a human trial? We have an anti-IL11 therapy specifically engineered for human ageing trials at https://t.co/KhbTu36Bz6. Needs investment, build out, approvable endpoints and not easy +++. But faster to humans… https://t.co/k1e5cDqTco
-
-
Mashup Score: 6
Abstract. Background: IL-11 is known as an inflammation-related factor, and it has been proved to be a key driver in fibrotic diseases. Besides, the roles of IL-11 in tumor immunopathology were recognized more in-depth and comprehensively in recent years. IL-11 expression is highly and positively correlated with overall survival in various cancer types, including colorectal cancer, hepatocellular carcinoma and lung cancer. It was reported that IL-11 promoted tumor cell growth and metastasis, mediated partly through its direct effects on macrophages, T cells and cancer-associated fibroblasts. All these studies indicated that blocking IL-11 signaling may be a promising therapeutic approach for the treatment of solid tumors. In this report, 9MW3811, a high-affinity IL-11 blocking antibody was developed to test its anti-tumor activity and synergistic effects with anti-PD-1 antibody in mouse tumor models.Methods: 9MW3811 was generated by mouse hybridoma technology followed by antibody human
Source: aacrjournals.orgCategories: General Medicine News, Cardiologists1Tweet-
Most interesting: “Our results demonstrated profound antitumor activity of 9MW3811 [anti-IL11] in different tumor models. 9MW3811 is currently in phase I clinical trials in AU, CN and US.” 👀 https://t.co/fRqppT6BUQ
-
-
Mashup Score: 5
Abstract. Background: IL-11 is known as an inflammation-related factor, and it has been proved to be a key driver in fibrotic diseases. Besides, the roles of IL-11 in tumor immunopathology were recognized more in-depth and comprehensively in recent years. IL-11 expression is highly and positively correlated with overall survival in various cancer types, including colorectal cancer, hepatocellular carcinoma and lung cancer. It was reported that IL-11 promoted tumor cell growth and metastasis, mediated partly through its direct effects on macrophages, T cells and cancer-associated fibroblasts. All these studies indicated that blocking IL-11 signaling may be a promising therapeutic approach for the treatment of solid tumors. In this report, 9MW3811, a high-affinity IL-11 blocking antibody was developed to test its anti-tumor activity and synergistic effects with anti-PD-1 antibody in mouse tumor models.Methods: 9MW3811 was generated by mouse hybridoma technology followed by antibody human
Source: aacrjournals.orgCategories: General Medicine News, Cardiologists1Tweet-
Most interesting: “Our results demonstrated profound antitumor activity of 9MW3811 [anti-IL11] in different tumor models. 9MW3811 is currently in phase I clinical trials in AU, CN and US.” 👀 https://t.co/fRqppT6BUQ
-
Bi-specific Anti-IL11 + Anti-TSLP Perhaps for asthma? Field moving fast https://t.co/LHbKo5Vs4o